The strong momentum of national biotech companies has been partly due to the pandemic. But also due to the increased interest of investment funds in them. Innovación from El Mercurio analyzed the phenomenon.
According to data from the ACVC, between 2012 and 2019, about US$ 20 million were invested in national biotech startups. But between 2020 and 2021, investment has risen exponentially with funds raised by NotCo, PhageLab, Protera, and Done Properly.
Markus Schreyer, founder, and CEO of The Ganesha Lab, affirms that these experiences and the context of the covid have improved the perspectives “by making it more common to speak of biotechnology as an area of development of technological ventures. We are in a moment of change and maturation like few others, and you have to keep pushing to take advantage of it at the country level.”
Francisco Guzmán, president of the ACVC, assures that biotechnology represents a relevant factor for Chile. “This rising curve has been going on for ten years, especially in the venture capital area. As a result of the pandemic, this curve increased exponentially. Both in the number of projects and in the increase in investment.”
Check the note at https://bit.ly/3F4uVny